Marco Matos

1.5k total citations
8 papers, 72 citations indexed

About

Marco Matos is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Marco Matos has authored 8 papers receiving a total of 72 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Cancer Research and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Marco Matos's work include Cancer Cells and Metastasis (5 papers), Cancer Genomics and Diagnostics (3 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Marco Matos is often cited by papers focused on Cancer Cells and Metastasis (5 papers), Cancer Genomics and Diagnostics (3 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Marco Matos collaborates with scholars based in Australia, New Zealand and China. Marco Matos's co-authors include David Wyld, David E. Martin, Brett Hughes, Jason D. Lickliter, Cu‐Tai Lu, Alfred K. Lam, Vinod Gopalan, Joseph C. Lee, Andrew D. Clouston and David Macfarlane and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

Marco Matos

7 papers receiving 71 citations

Peers

Marco Matos

GENET

ONCOL

CR

PRM

MB

Stacey Green United States

Ian Robins United States

Izac J. Findlay Australia

Macarena de la Fuente United States

Christine Ann Pittman Ballard United States

Lucía Zhu Spain

Duna Barakeh Saudi Arabia

Lyndon J. Kim United States

Dan Christian Chiforeanu France

Natalia Miheecheva United States

Stacey Green United States

Marco Matos

53 ×1.2

GENET

17 ×0.6

ONCOL

18 ×0.7

CR

16 ×0.8

PRM

31 ×1.8

MB

Citations per year, relative to Marco Matos Marco Matos (= 1×) peers Stacey Green

Countries citing papers authored by Marco Matos

Since Specialization

Citations

This map shows the geographic impact of Marco Matos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Matos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Matos more than expected).

Fields of papers citing papers by Marco Matos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Matos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Matos. The network helps show where Marco Matos may publish in the future.

Co-authorship network of co-authors of Marco Matos

This figure shows the co-authorship network connecting the top 25 collaborators of Marco Matos. A scholar is included among the top collaborators of Marco Matos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco Matos. Marco Matos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Desai, Jayesh, Sanjeev Deva, Bo Gao, et al.. (2025). A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti–PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results. Cancer Chemotherapy and Pharmacology. 95(1). 99–99.

2.

Matos, Marco, George Kannourakis, Morteza Aghmesheh, et al.. (2025). Safety, tolerability, and preliminary efficacy of tinodasertib as a monotherapy or in combination with pembrolizumab or irinotecan in metastatic colorectal cancer: Interim results from a phase II open-label, dose-finding, run-in and cohort expansion study.. Journal of Clinical Oncology. 43(4_suppl). 183–183. 1 indexed citations

3.

Desai, Jayesh, Diwakar Davar, Sanjeev Deva, et al.. (2023). A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors.. Journal of Clinical Oncology. 41(16_suppl). 2574–2574. 4 indexed citations

4.

Lu, Cu‐Tai, et al.. (2021). Enumeration, characterisation and clinicopathological significance of circulating tumour cells in patients with colorectal carcinoma. Cancer Genetics. 254-255. 48–57. 3 indexed citations

5.

Gopalan, Vinod, et al.. (2020). Genetic Heterogeneity of Single Circulating Tumour Cells in Colorectal Carcinoma. International Journal of Molecular Sciences. 21(20). 7766–7766. 10 indexed citations

6.

Lu, Cu‐Tai, et al.. (2020). Abstract 5367: Identification and clinical value of the circulating tumor cells (CTCs) in the colorectal cancer. Cancer Research. 80(16_Supplement). 5367–5367. 2 indexed citations

7.

Matos, Marco, et al.. (2010). Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. Journal of Clinical Neuroscience. 17(8). 970–974. 48 indexed citations

8.

Matos, Marco, et al.. (2009). Nesidioblastosis as a cause of focal pancreatic 111In-pentetreotide uptake in a patient with putative VIPoma: another differential diagnosis. Annals of Nuclear Medicine. 23(5). 497–499. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact